Organ Dysfunction

Carfilzomib

Description:

Carfilzomib is a selective proteasome inhibitor. This Phase I study is evaluating the safety of Carfilzomib in patients with advanced solid tumors or hematological malignancies and varying degrees of hepatic impairment. It is administered on days 1, 2, 8, 9, 15, and 16 during a 28 day cycle.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

Crizotinib

Description:

Crizotinib is orally bioavailable ALK and c-MET/HGFR receptor tyrosine kinases inhibitor. This Phase I study evaluates the effect of hepatic impairment on the pharmacokinetics and safety of Crizotinib in advanced cancer patients with solid tumors.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Contact: Epp Goodwin at (210) 450-5798

Halaven

Description:

Halaven is a synthetic analogue of the marine spong natural product halichondrinB. As an inhibitor of microtubules it blocks the cell division and leads to apoptosis of the cancer cells. In this study Halaven is administered on days 1 and 8 of a 21 day cycle in patients with solid tumors who also have impaired renal function.


Type(s) of Cancer: Organ Dysfunction
Study Phase(s): Phase I
Category: Organ Dysfunction
Contact: Epp Goodwin at (210) 450-5798